Minoo Shahidi
Department of Hematology and Blood Banking, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran & Cellular and Molecular Research Center (CMRC), Iran University of Medical Sciences, Tehran, Iran.
[ 1 ] - AMG-232, a New Inhibitor of MDM-2,Enhance Doxorubicin Efficiency in Pre-B Acute Lymphoblastic Leukemia Cells
Background: Doxorubicin (DOX)-induced cardiotoxicity appears to be a growing concern for extensive use in acute lymphoblastic leukemia (ALL). The new combination treatment strategies, therefore might be an effective way of decreasing its side effects as well as improving efficacy. AMG232 (KRT-232) is a potential MDM-2 inhibitor, increasing available p53 through disturbing p53-MDM-2 interaction....
Co-Authors